Billy Joel has been performing his hit songs all over the world for decades, but a recent concert in Connecticut didn't go as ...

Obesity is a major risk factor for joint failure because excess weight puts more stress on the implants, leading to ...

Shares of WW International (NASDAQ:WW) have reversed Thursday’s after-hours gains as guarded remarks from the company’s CEO ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Convenience company trying to understand potential impact of tariffs, but its system ‘designed to allow us to source barrels ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

In Wednesday's "Need to Know" column, Barbara Kollmeyer shared words of wisdom from Larry Swedroe, who has written many books about investing during a long career managing money. He quoted Buffett and ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...